CL2012000551A1 - Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea. - Google Patents

Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.

Info

Publication number
CL2012000551A1
CL2012000551A1 CL2012000551A CL2012000551A CL2012000551A1 CL 2012000551 A1 CL2012000551 A1 CL 2012000551A1 CL 2012000551 A CL2012000551 A CL 2012000551A CL 2012000551 A CL2012000551 A CL 2012000551A CL 2012000551 A1 CL2012000551 A1 CL 2012000551A1
Authority
CL
Chile
Prior art keywords
cea
antigen
binds
binding domain
polypep
Prior art date
Application number
CL2012000551A
Other languages
English (en)
Inventor
Ekkehard Moessner
Ralf Hosse
Pablo Umana
Thomas U Hofer
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2012000551A1 publication Critical patent/CL2012000551A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Molécula de unión a antígeno (ABM) porque dicho dominio de unión a antígeno se une específicamente a antígeno carcinoembrionario humano (CEA) unido a membrana; polipep que comprende dominio de unión a antígeno que se une a CEA; anticuerpo que se une a CEA; composición que comprende moléculas que se unen a CEA.
CL2012000551A 2009-08-31 2012-02-29 Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea. CL2012000551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23850509P 2009-08-31 2009-08-31

Publications (1)

Publication Number Publication Date
CL2012000551A1 true CL2012000551A1 (es) 2012-10-12

Family

ID=42985489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000551A CL2012000551A1 (es) 2009-08-31 2012-02-29 Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.

Country Status (23)

Country Link
US (2) US9068008B2 (es)
EP (1) EP2473532B1 (es)
JP (1) JP5744872B2 (es)
KR (1) KR101528013B1 (es)
CN (1) CN102741293B (es)
AR (1) AR078111A1 (es)
AU (1) AU2010288469A1 (es)
BR (1) BR112012003983A2 (es)
CA (1) CA2770174A1 (es)
CL (1) CL2012000551A1 (es)
CO (1) CO6491105A2 (es)
CR (1) CR20120087A (es)
EC (1) ECSP12011698A (es)
HK (1) HK1176951A1 (es)
IL (1) IL218038A0 (es)
MA (1) MA33536B1 (es)
MX (1) MX339608B (es)
PE (1) PE20121552A1 (es)
RU (1) RU2570554C2 (es)
SG (1) SG178567A1 (es)
TW (1) TW201121994A (es)
WO (1) WO2011023787A1 (es)
ZA (1) ZA201200954B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
AU2002339845B2 (en) 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
MX347590B (es) 2011-03-02 2017-05-03 Roche Glycart Ag Anticuerpos del cea.
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP6159724B2 (ja) 2011-08-23 2017-07-05 ロシュ グリクアート アーゲー Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method
JP6290209B2 (ja) 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー 低下した及び増加したエフェクター機能を有するように操作された２つの抗体を含む組成物。
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
RU2015140917A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP3708584A1 (en) 2013-02-26 2020-09-16 Roche Glycart AG Bispecific t cell activating antigen binding molecules
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
MD20160130A2 (ro) 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Anticorpi umanizaţi contra CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CA2951599A1 (en) 2014-08-04 2016-02-11 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CR20180162A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
CN115920030A (zh) 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
DK3433280T3 (da) 2016-03-22 2023-06-19 Hoffmann La Roche Protease-aktiverede T-celle-bispecifikke molekyler
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
PL3519437T3 (pl) 2016-09-30 2022-01-17 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste przeciwko p95HER2
BR112020016169A2 (pt) 2018-02-08 2020-12-15 Genentech, Inc. Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit
CN114127123A (zh) 2019-06-26 2022-03-01 豪夫迈·罗氏有限公司 结合cea的抗体与4-1bbl的融合
JP2022539344A (ja) * 2019-06-26 2022-09-08 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｅａ抗体及びその応用
CN110862456B (zh) * 2019-09-23 2021-04-09 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
IL298402A (en) 2020-06-19 2023-01-01 Hoffmann La Roche Antibodies that bind to CD3 and CD19
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating CEACAM-positive cancer
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2023147426A2 (en) * 2022-01-27 2023-08-03 Janssen Biotech, Inc. Enhanced protein compositions
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE203168T1 (de) * 1992-05-07 2001-08-15 Nycomed Imaging As Komplexbildnermittel und zielimmunoreagenzien
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US6815184B2 (en) 2000-07-31 2004-11-09 Biolex, Inc. Expression of biologically active polypeptide in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002339845B2 (en) 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1467615B2 (en) 2001-12-27 2017-03-22 GlycoFi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
JP5350573B2 (ja) 2002-03-19 2013-11-27 スティヒティング ディーンスト ランドバウクンディフ オンデルズーク 植物におけるｇｎｔｉｉｉ発現
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2003248982B2 (en) * 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
SI1539966T1 (sl) 2002-09-12 2010-10-29 Greenovation Biotech Gmbh Postopek za produkcijo proteinov
WO2004057002A2 (en) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
EP1627062A1 (en) * 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
MX347590B (es) * 2011-03-02 2017-05-03 Roche Glycart Ag Anticuerpos del cea.

Also Published As

Publication number Publication date
KR101528013B1 (ko) 2015-06-16
MX339608B (es) 2016-05-31
JP5744872B2 (ja) 2015-07-08
RU2570554C2 (ru) 2015-12-10
US20160075795A1 (en) 2016-03-17
ZA201200954B (en) 2014-07-30
AR078111A1 (es) 2011-10-12
CR20120087A (es) 2012-03-22
CO6491105A2 (es) 2012-07-31
MA33536B1 (fr) 2012-08-01
TW201121994A (en) 2011-07-01
CA2770174A1 (en) 2011-03-03
PE20121552A1 (es) 2012-11-26
BR112012003983A2 (pt) 2021-09-14
WO2011023787A1 (en) 2011-03-03
RU2012112340A (ru) 2013-10-10
AU2010288469A1 (en) 2012-03-01
IL218038A0 (en) 2012-04-30
SG178567A1 (en) 2012-04-27
EP2473532B1 (en) 2017-06-21
CN102741293A (zh) 2012-10-17
EP2473532A1 (en) 2012-07-11
JP2013502913A (ja) 2013-01-31
US20110104148A1 (en) 2011-05-05
HK1176951A1 (en) 2013-08-09
CN102741293B (zh) 2015-04-01
ECSP12011698A (es) 2012-03-30
KR20120060874A (ko) 2012-06-12
MX2012002461A (es) 2012-03-14
US9068008B2 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
CL2012000551A1 (es) Molecula de union a antigeno (abm) porque dicho dominio de union a antigeno se une especificamente a antigeno carcinoembrionario humano (cea) unido a membrana; polipep que comprende dominio de union a antigeno que se une a cea; anticuerpo que se une a cea; composicion que comprende moleculas que se unen a cea.
CY1119287T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης-αντι-her2
CL2020000830A1 (es) Molécula de unión a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epítope de cd3 humano y de mamíferos no humanos; composición farmacéutica que comprende dicha molécula y su uso. (divisional solicitud 201303329)
CR20140585A (es) Proteinas de union a antigeno st2
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1118906T1 (el) Χαμηλης συγγενειας αντισωματα υποδοχεα αιματοεγκεφαλικου φραγμου και χρησεις αυτων
NI201200052A (es) Anticuerpos que se unen específicamente al receptor epha2
BRPI0812777A2 (pt) Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
CL2011002380A1 (es) Anticuerpo multiespecifico que comprende un anticuerpo de longitud completa que se une especificamente a un primer antigeno y uno o mas fragmentos fab de cadena sencilla que se unen a uno o mas antigenos, acido nucleico que lo codifica; y composicion farmaceutica que lo comprende.
CR20110577A (es) Proteínas de unión a il-1
UA114707C2 (uk) БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2
EA201300978A1 (ru) Антитела к сеа
DOP2009000236A (es) Anticuerpos de union a antigenos multiples
AR080513A1 (es) Moleculas de union cd37 y sus inmunoconjugados
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
AU2010234031A8 (en) Trivalent, bispecific antibodies
CO7400860A2 (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos
CR20130128A (es) Nuevas proteínas de unión a antígenos
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
CR20110238A (es) Anticuerpos muc1*
CR20110566A (es) Inmunoconjugados de antimesotelina y usos de los mismos
CL2011002306A1 (es) Anticuerpo o un fragmento de union a antigeno del mismo que se une especificamente a la integrina heterodimero alfa4beta7; y composicion que lo comprende.